Business Context and Reporting Period
This Form 8-K is filed by Martin Midstream Partners L.P. on June 15, 2010, reporting events that occurred on June 10, 2010. The filing addresses a governance issue regarding the composition of the Audit Committee of the Partnership's general partner, Martin Midstream GP LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report focused on corporate governance and listing compliance rather than financial performance.
Material Changes
- Board Resignation: John P. Gaylord resigned from his positions on the Board of Directors and the Audit Committee of Martin Midstream GP LLC on June 10, 2010.
- Listing Non-Compliance: The resignation reduced the Audit Committee to two independent members, resulting in non-compliance with Nasdaq Listing Rule 5605(c)(2)(A), which mandates a minimum of three independent members.
- Regulatory Notice: On June 15, 2010, the Partnership received formal notice from Nasdaq confirming the non-compliance status.
Guidance, Outlook, and Risks
- Cure Period: Under Nasdaq Listing Rule 5605(c)(4)(B), the Partnership has a one-year cure period to regain compliance, with a deadline of May 24, 2011.
- Management Action: The Partnership intends to fill the vacancy on the Audit Committee as expeditiously as possible.
- Risk: Failure to regain compliance by the deadline could result in delisting or other enforcement actions by Nasdaq.
Key Facts for Investor Verification
- Verify the timeline for appointing a new independent director to the Audit Committee.
- Confirm the current status of the Audit Committee composition relative to the May 24, 2011 deadline.
- Review any subsequent filings regarding the appointment of a replacement for John P. Gaylord.